Filter by content type
Filter by year
2022 HNSCC Symposium Poster: Phase 1/2 study of pepinemab in combination with pembrolizumab as first-line treatment of advanced, recurrent or metastatic head and neck cancer (KEYNOTE B84)
Pagination
- Previous page
- Page 2
- Next page